Drug shortages homepage

Welcome to Drug Shortages Canada, the website for mandatory reporting of drug shortages and discontinuations by market authorization holders. Anyone can search the database of shortage and discontinuation reports. More information can be found on the About & Resources Page.

Early reporting of shortages and discontinuations provides Health Canada, provincial/territorial governments, drug supply chain stakeholders, and health professionals details needed to help them monitor and manage supply. Shortages can be caused by many factors. Some last longer and are more complex than others. Because companies have to report every time they cannot fully meet demand, not all of the reports on this site are cause for concern at the patient level. Most are successfully managed before they impact patients.

The shortage database has a flag that indicates ones that are Tier 3 drug shortages, which are those that could potentially have the highest impact on Canada's drug supply and health care system. A Tier 3 designation is decided by the Tier Assignment Committee (TAC), composed of federal and provincial/territorial governments, healthcare professionals, and industry stakeholders.

Ensuring people can get the medicines they need is a top priority for Health Canada. Health Canada works closely with many partners to prevent shortages, mitigate their impacts, and help resolve them when they occur.

If you would like to know more about shortages like why they happen, how long they last, the actions being taken to reduce impacts on Canadians, and actions you can take if a drug you use is in shortage, please consult the information on Canada.ca.

Below are the newest shortage and discontinuation reports and updates to existing ones.

Drug pills

LEGEND

!!T3 denotes an actual Tier 3 shortage/discontinuation

!T3 denotes an anticipated Tier 3 shortage/discontinuation

Shortage Reports

Brand name Company Name Status Strength Update Date Updated View Report
XYLOCAINE 2% WITH EPINEPHRINE 1:200000 ASPEN PHARMACARE CANADA INC. Actual shortage 0.005MG 20MG Updated Report 2024-05-21 220855
XYLOCAINE 1% W EPINEPHRINE 1:100000 ASPEN PHARMACARE CANADA INC. Actual shortage 0.01MG 10MG Updated Report 2024-05-21 220858
XYLOCAINE 2% W EPINEPHRINE 1:200000 ASPEN PHARMACARE CANADA INC. Actual shortage 5MCG 20MG Updated Report 2024-05-21 222670
GD-DICLOFENAC/MISOPROSTOL 50 GENMED A DIVISION OF PFIZER CANADA ULC Actual shortage 200MCG 50MG Updated Report 2024-05-21 220932
EMLA CREAM ASPEN PHARMACARE CANADA INC. Actual shortage 2.5% 2.5% Updated Report 2024-05-21 222665
SANDOZ PRAVASTATIN TABLETS SANDOZ CANADA INCORPORATED Resolved 20MG Updated Report 2024-05-18 224645
SANDOZ PRAVASTATIN TABLETS SANDOZ CANADA INCORPORATED Resolved 40MG Updated Report 2024-05-18 224648
VISIPAQUE 270 GE HEALTHCARE CANADA INC Resolved 550MG Updated Report 2024-05-18 227151
SANDOZ SENNA S SANDOZ CANADA INCORPORATED Resolved 50MG 8.6MG Updated Report 2024-05-18 227201
HEPARIN SODIUM INJECTION USP (MULTIDOSE VIAL-WITH PRESERVATIVE) SANDOZ CANADA INCORPORATED Resolved 10000UNIT Updated Report 2024-05-18 227194

Discontinuation Reports

Brand name Company Name Status Strength Update Date Updated View Report
HEPARIN SODIUM INJECTION USP (MULTIDOSE VIAL-WITH PRESERVATIVE) SANDOZ CANADA INCORPORATED Discontinued 10000UNIT Updated Report 2024-05-18 228249
SANDOZ PRAVASTATIN TABLETS SANDOZ CANADA INCORPORATED Discontinued 20MG Updated Report 2024-05-18 228256
SANDOZ PRAVASTATIN TABLETS SANDOZ CANADA INCORPORATED Discontinued 40MG Updated Report 2024-05-18 228263
SANDOZ SENNA S SANDOZ CANADA INCORPORATED Discontinued 50MG 8.6MG Updated Report 2024-05-18 228268
SUPREFACT DEPOT 3 MONTHS CHEPLAPHARM ARZNEIMITTEL GMBH Discontinued 9.45MG Updated Report 2024-05-17 228166